Machine Learning

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

A new 24g wearable device promises clinic-grade laser therapy for just $99. Can its high-power science truly democratize healing, or is it just hype?

Praxis Precision Medicines secures a clear path to market for its rare epilepsy drug, blending genetic science with a savvy regulatory strategy.

With leadership buying shares and promising trial data for its novel cancer drug, MAIA Biotechnology is sending strong signals to investors. What's next?

As esports races toward a $7.5B market, specialized hardware is king. Inside ZOWIE's strategy to win the high-stakes game of competitive tech.

A once-failed class of weight-loss drugs is back with a new design. Corbus Pharma's early data suggests it may have solved the safety puzzle.

After a decade of failed trials, a new drug shows promise in treating resistant lung cancer by reawakening the immune system and halting its spread.

A breakthrough genetic therapy for ALS offers hope, but a split verdict from Canadian health agencies reveals the tough calculus of innovation versus cost.

Promising interim data for a Parkinson's vaccine sends AC Immune's stock soaring, signaling a potential paradigm shift from symptom management to disease modification.

With $70M and a new CEO, Prolynx is leveraging a cancer-tested platform to create monthly obesity shots. Can it disrupt a billion-dollar market?

With AI-guided drills and a new discovery, Nevada King aims to transform its Atlanta mine into a major US gold asset. Will the market take notice?

Canadian grocer Empire posts strong sales but lower earnings. A deep dive into its dual strategy of store renewal and a major digital and data overhaul.

Rezolute's stock plummets after its lead drug fails a key trial, raising questions about its future and highlighting the brutal realities of biotech.

Dreame's 2025 holiday sale isn't just about vacuums; it's a strategic play to conquer the UK market with premium tech at aggressive prices.

Fidelity and TIAA still lead, but strategic AI investments are fueling a surge from mid-tier players, redefining the competitive retirement landscape.

Advantest's T2000 AiR2X isn't just new hardware. It's a calculated move to solve the chip industry's legacy pains and efficiency demands.

How Circus SE's autonomous robot is set to revolutionize corporate dining, tackling food waste and augmenting the workforce at a top auto plant.

OMRON's new global ECG strategy leverages AI and key acquisitions to tackle heart disease, aiming to eliminate adverse cardiovascular events.

Glance is partnering with IAS to bring ad verification to 250M+ users in India and Indonesia, a strategic move to combat fraud and lure premium brands.

BTCC's integration with TradingView signals a major industry shift, bringing professional-grade tools and seamless execution to the crypto futures market.